Aug 2026· Frontiers in Immunology· Vol 17· 0 citations· 60 references
Medicine
TL;DR
PNS involvement in anti-NMDAR encephalitis is not uncommon and most frequently manifests as acute or subacute limb weakness, and PNS involvement was not significantly associated with disease prognosis.
Abstract
Background Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is the most common autoimmune encephalitis, primarily affecting the central nervous system (CNS) and typically presenting with neuropsychiatric symptoms. However, emerging evidence suggests that peripheral nervous system (PNS) involvement may also occur in some cases. Objective To investigate the clinical and neuro-electrophysiological characteristics of PNS involvement in patients with positive anti-NMDAR antibodies in cerebrospinal fluid (CSF). Methods We retrospectively reviewed all patients with CSF-confirmed anti-NMDAR encephalitis at the Second Affiliated Hospital of Guangzhou Medical University between 2016 and 2025. Collected data included initial symptoms and disease severity, CSF and serum test results, magnetic resonance imaging (MRI) and neuro-electrophysiological findings, primary treatment regimens, presence of coexisting autoimmune disorders, and clinical outcomes. Results Among the 46 patients with anti-NMDAR encephalitis, 9 patients (19.6%) exhibited PNS involvement. The average age of onset in this subgroup with PNS involvement were significantly older than those with CNS involvement only (mean ± SD: 36.2 ± 18.9 years vs. 24.6 ± 12.4 years; P = 0.029). Limb weakness was significantly more frequent in the PNS involvement group (55.6% vs. 2.7%; P < 0.001). Electromyography (EMG) was performed in 18 patients (39.1%), of whom 10 patients (55.6%) showed abnormal findings. Among these, 1 patient exhibited active radiculopathy associated with motor neuron disease, 2 patients had isolated radiculopathy, and 1 patient presented with mixed polyneuropathy involving both motor and sensory functions. Cranial nerve involvement was observed in 2 patients (22.2%). In one case, PNS involvement was the initial symptom. All patients received first-line immunotherapy. PNS involvement was not significantly associated with disease prognosis. Conclusion PNS involvement in anti-NMDAR encephalitis is not uncommon and most frequently manifests as acute or subacute limb weakness. Neuro- electrophysiological abnormalities predominantly involve motor conduction pathways and proximal nerve roots. This is a single-center retrospective study with a small sample size. Large-sample prospective studies are needed to further validate the findings.
Findings support the possibility that anti-mGluR1 encephalitis may, in rare instances, present with predominant brainstem involvement and testing for anti-mGluR1 antibodies may be considered in patients with otherwise unexplained subacute inflammatory brainstem syndromes.
Anti-N-methyl-D-aspartate receptor encephalitis (anti-NMDAR-E) is a severe autoimmune encephalitis that predominantly affects young women and is frequently associated with ovarian teratomas. Increasing evidence indicates that these tumors play a central role in disease initiation by providing a peripheral immunological...
Hanna Miski, Kamila Krupa, Bartosz Balasiewicz et al.· Biomedicines· 0 citations
It is suggested that complement inhibition may facilitate rapid neurological recovery and may represent a potential therapeutic strategy for selected patients with severe anti-NMDAR encephalitis.
Yang Liu, Yu-Jing Yuan, Yingjie Zhang et al.· Journal of Neuroimmunology· 0 citations
Background Anti-γ-aminobutyric acid A receptor (GABAA receptor) encephalitis is a rare but severe subtype of autoimmune encephalitis (AE), typically characterized by refractory seizures and rapidly progressive neurological dysfunction. Although structural abnormalities on magnetic resonance imaging (MRI) are frequently...
Yi Huang, Jia-Yue Li, Qi Gao et al.· Frontiers in Immunology· 0 citations
Rationale: Autoimmune encephalitis in children often presents with neuropsychiatric symptoms and seizures and may progress to secondary epilepsy with prolonged functional impairment. Immunotherapy is the principal disease-modifying treatment, whereas comprehensive nursing care supports safety, complication prevention,...
During disease progression, innovative sequential therapy with efgartigimod, an FcRn antagonist, was followed by the anti-CD20 monoclonal antibody rituximab (RTX) to reduce the risk of profound B-cell depletion, thereby demonstrating synergistic efficacy.
Jun-Tong Liu, Wen-Ping Zhu, Lan Gao et al.· Frontiers in Immunology· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.